Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%

Oestrogen therapy alone vs placebo

Venous thromboembolism · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 2.22 [1.12, 4.39]
1 study · 10739 participants
Moderate

Oestrogen therapy alone vs placebo

Venous thrombo‐embolism (DVT or PE): CEE 0.625 mg (moderate dose) · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) showed no clear difference in venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.32 [1, 1.74]
1 study · 10739 participants
Moderate

Oestrogen therapy alone vs placebo

Breast cancer · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) showed no clear difference in breast cancer compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 0.79 [0.61, 1.01]
1 study · 10739 participants
Moderate

Oestrogen therapy alone vs placebo

Gallbladder disease · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.78 [1.42, 2.24]
1 study · 8376 participants
Moderate

Oestrogen therapy alone vs placebo

All clinical fractures · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 0.73 [0.65, 0.8]
1 study · 10739 participants
Moderate

Oestrogen therapy alone vs placebo

Coronary events (MI or cardiac death) · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) showed no clear difference in coronary events (MI or cardiac death) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 0.94 [0.78, 1.13]
1 study · 10739 participants
Moderate

Oestrogen therapy alone vs placebo

Stroke · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) probably leads to higher stroke compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.33 [1.06, 1.67]
1 study · 10739 participants
Moderate